Paper - WANFANG MED ONLINE

You Position: Home > Paper

肺癌免疫检查点抑制剂治疗:从临床研究到临床实践

( views:240, downloads:885 )

Author:: No author available

Journal Title:: Chinese Journal of Tuberculosis and Respiratory Diseases

Issue:: 2

DOI:: 10.3760/cma.j.issn.1001-0939.2020.02.006

Key Word:: No keyword available

Abstract：肺癌是全球范围内发生率和死亡率最高的恶性肿瘤.近年来,免疫检查点抑制剂在非小细胞肺癌和小细胞肺癌的治疗中均有突破,改变了肺癌治疗策略的格局,也改善了患者的生存结局.本文对免疫检查点抑制剂在肺癌治疗中的使用时机、疗效、安全性和适用人群进行探讨.

Reference

[1]A, Lisberg,A, Cummings,J W, Goldman,etc.A Phase II Study of Pembrolizumab in EGFR-mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Na?ve Patients with Advanced NSCLC.[J].2018,(Spec ).
[2]Neal Ready,Anna F. Farago,Filippo de Braud,etc.Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032[J].2019,14(2).
[3]Rizvi, Naiyer A.,Hellmann, Matthew D.,Brahmer, Julie R.,etc.Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer[J].2016,34(25).
[4]Wang, Jun,Sanmamed, Miguel F.,Datar, Ila,etc.Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3.[J].2019,176(1-2).
[5]Antonia, Scott,Goldberg, Sarah B.,Balmanoukian, Ani,etc.Safety and antitumour activity of durvalumab plus tremelimumab in non-small-cell lung cancer: a multicentre, phase 1b study[J].2016,17(3).
[6]Horn, Leora,Geese, William J.,Spigel, David,etc.Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study[J].2018,36(17).
[7]Yi-Long,Wu,Shun,Lu,Ying,Cheng,etc.Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial.[J].2019,14(5).
[8]Martin Peifer,Lawryn H Kasper,Lynnette Fernandez-Cuesta,etc.Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer[J].2012,44(10).
[9]Herbst, Roy S.,Baas, Paul,Kim, Dong-Wan,etc.Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial[J].2016,387(10027).
[10]Reck, Martin,Rodriguez-Abreu, Delvys,Robinson, Andrew G.,etc.Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer[J].2016,375(19).
[11]Socinski, M. A.,Jotte, R. M.,Cappuzzo, F.,etc.Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC[J].2018,378(24).
[12]Velez, Moises J.,Chaft, Jamie E.,Hellmann, Matthew D.,etc.Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors[J].2017,104(3).
[13]Gettinger, Scott,Rizvi, Naiyer A.,Chow, Laura Q.,etc.Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer[J].2016,34(25).
[14]Chee Khoon, Lee,Johnathan, Man,Sally, Lord,etc.Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.[J].2017,(Spec ).
[15]Rittmeyer, Achim,Barlesi, Fabrice,Waterkamp, Daniel,etc.Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial[J].2017,389(10066).
[16]Scott J,Antonia,Augusto,Villegas,Davey,Daniel,etc.Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.[J].2018.
[17]Borghaei, H.,Paz-Ares, L.,Horn, L.,etc.Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer[J].2015,373(17).
[18]Tony S K,Mok,Yi-Long,Wu,Iveta,Kudaba,etc.Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.[J].2019,393(10183).
[19]Hellmann, Matthew D.,Rizvi, Naiyer A.,Goldman, Jonathan W.,etc.Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study[J].2017,18(1).
[20]Hossein Borghaei,Corey J. Langer,Shirish Gadgeel,etc.24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for?Advanced Nonsquamous Non-Small Cell Lung?Cancer[J].2019,14(1).
[21]Bray Freddie,Ferlay Jacques,Soerjomataram Isabelle,etc.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].2018,68(6).
[22]Carbone, D. P.,Reck, M.,Paz-Ares, L.,etc.First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer[J].2017,376(25).
[23]Gandhi, L.,Rodriguez-Abreu, D.,Gadgeel, S.,etc.Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer[J].2018,378(22).
[24]Antonia, Scott J.,Lopez-Martin, Jose A.,Bendell, Johanna,etc.Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial[J].2016,17(7).
[25]Fehrenbacher, Louis,Spira, Alexander,Ballinger, Marcus,etc.Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial[J].2016,387(10030).
[26]Garon, Edward B.,Rizvi, Naiyer A.,Hui, Rina,etc.Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer[J].2015,372(21).
[27]Brahmer, Julie,Reckamp, Karen L.,Baas, Paul,etc.Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer[J].2015,373(2).
[28]Forde, P. M.,Chaft, J. E.,Smith, K. N.,etc.Neoadjuvant PD-1 Blockade in Resectable Lung Cancer[J].2018,378(21).
[29]Csoszi, T.,Gumus, M.,Rodriguez-Cid, J.,etc.Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer[J].2018,379(21).
[30]Yi, John S.,Ready, Neal,Healy, Patrick,etc.Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab[J].2017,23(24).